Summary
In addition to other distressing symptoms, palliative patients often suffer from very severe pain. For this reason, a precise pain diagnosis is necessary in order to be able to initiate the necessary therapeutic measures. Pain therapy includes the medications specified in the World Health Organization (WHO) analgesic ladder as well as various supportive measures.
Similar content being viewed by others
References
Smith AK, et al. The epidemiology of pain during the last 2 years of life. Ann Intern Med. 2010;153:563–9.
Gill TM, Han L, Leo-Summers L, Gahbauer EA, All-ore HG. Distressing symptoms, disability, and hospice services at the end of life: prospective cohort study. J Am Geriatr Soc. 2018;66(1):41–7. https://doi.org/10.1111/jgs.15041.
Bostwick D, Wolf St, Samsa G, et al. Comparing the palliative care needs of those with cancer to those with common non-cancer serious illness. J Pain Symptom Manage. 2017;53(6):1079–1084.e1.
Köstenberger M, Neuwersch S, Weixler D, Pipam W, Zink M, Likar R. Prevalence of palliative care patients in emergency departments. Wien Klin Wochenschr. 2019;131(17–18):404–9. https://doi.org/10.1007/s00508-019-1530-5.
World Health Organization. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. CC BY-NC-SA 3.0 IGO. Geneva: WHO; 2018.
Anekar AA, Cascella M. WHO analgesic ladder. 2020. https://www.ncbi.nlm.nih.gov/books/NBK554435/. Accessed 17 May 2020.
https://www.basg.gv.at/fileadmin/redakteure/06_Gesundheitsberufe/DHPC/2013/131028_Diclofenac-1.pdf. Accessed 24 Jan 2021.
European Medicines Agency. PRAC recommends the samecardiovascular precautions for diclofenac as for selective COX‑2 inhibitors. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/06/WC500144451.pdf. Accessed 24 Jan 2021.
European Medicines Agency. New safety advice for diclofenac. New measures aim to minimise cardiovascular risks. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Diclofenaccontaining_medicinal_products/European_Commission_final_decision/WC500155819.pdf. Accessed 24 Jan 2021.
European Medicines Agency. PRAC recommends updating advice on use of high-dose ibuprofen. Review confirms small increased cardiovascular risk with daily doses at or above 2,400 mg. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2015/04/WC500185426.pdf. Accessed 24 Jan 2021.
Reinecke H, Sorgatz H. S3 guideline LONTS. Long-term administration of opioids for non-tumor pain. Schmerz. 2009;23(5):440–7. https://doi.org/10.1007/s00482-009-0839-9.
Heiskanen T, Mätzke S, Haakana S, Gergov M, Vuori E, Kalso E. Transdermal fentanyl in cachectic cancer patients. Pain. 2009;144(1–2):218–22. https://doi.org/10.1016/j.pain.2009.04.012.
Chiba T, Takahashi H, Tairabune T, Kimura S, Ueda H, Kudo K. Cancer cachexia may hinder pain control when using fentanyl patch. Biol Pharm Bull. 2020;43(5):873–8. https://doi.org/10.1248/bpb.b19-01086.
Sittl R, Likar R, Nautrup PB. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin Ther. 2005;27(2):225–37.
Wilcock A, Charlesworth S, Toller CS, Girish R, Mihalyo M, Howard P. Denosumab: AHFS 92:24. J Pain Symptom Manage. 2018;56(2):295–301. https://doi.org/10.1016/j.jpainsymman.2018.05.021.
Porta-Sales J, Garzón-Rodríguez C, Llorens-Torromé S, Brunelli C, Pigni A, Caraceni A. Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: a systematic review within the European Association for Palliative Care guidelines project. Palliat Med. 2017;31(1):5–25. https://doi.org/10.1177/0269216316639793.
Rasche T, Emmert D, Radbruch L, et al. Cannabis und Cannabinoide in der Palliativversorgung. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019;62:830–5. https://doi.org/10.1007/s00103-019-02967-1.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
M. Köstenberger and R. Likar declare that they have no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Köstenberger, M., Likar, R. Pain and palliative care treatment in daily practice. memo 14, 53–57 (2021). https://doi.org/10.1007/s12254-021-00685-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12254-021-00685-6